| EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. | EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, Hsu JY, Oliphant MUJ, Armstrong B, Wessells V, Varella-Garcia M, Galbraith MD, Pierce A, Wang D, Venkataraman S, Danis E, Veo B, Serkova N, Espinosa JM, Gustafson DL, Vibhakar R, Ford HL., Free PMC Article | 12/22/2023 |
| Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase. | Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.
Anantharajan J, Baburajendran N, Lin G, Loh YY, Xu W, Ahmad NHB, Liu S, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Hung AW, Joy J, Hill J, Ford HL, Zhao R, Keller TH, Kang C., Free PMC Article | 03/26/2022 |
| EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling. | EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling.
Liu ZK, Li C, Zhang RY, Wei D, Shang YK, Yong YL, Kong LM, Zheng NS, Liu K, Lu M, Liu M, Hu CX, Yang XZ, Chen ZN, Bian H., Free PMC Article | 01/15/2022 |
| Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. | Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe.
Zhang G, Dong Z, Gimple RC, Wolin A, Wu Q, Qiu Z, Wood LM, Shen JZ, Jiang L, Zhao L, Lv D, Prager BC, Kim LJY, Wang X, Zhang L, Anderson RL, Moore JK, Bao S, Keller TH, Lin G, Kang C, Hamerlik P, Zhao R, Ford HL, Rich JN., Free PMC Article | 12/11/2021 |
| MicroRNA-219 inhibits cell viability and metastasis in papillary thyroid carcinoma by targeting EYA2. | MicroRNA-219 inhibits cell viability and metastasis in papillary thyroid carcinoma by targeting EYA2.
Liu HM, Dong AB, Hua H, Sun YH, Wang JR, Yu QQ, Zhang JH, Sun WH. | 05/8/2021 |
| The inhibition of AKT attenuated EYA2-induced Bcl-2 upregulation. In conclusion, our data demonstrated that Eya2 was upregulated in prostate cancers. EYA2 promotes cell proliferation and invasion as well as cancer progression by regulating docetaxel sensitivity and mitochondrial membrane potential, possibly via the AKT/Bcl-2 axis. | Eya2 Is Overexpressed in Human Prostate Cancer and Regulates Docetaxel Sensitivity and Mitochondrial Membrane Potential through AKT/Bcl-2 Signaling.
Liu Z, Zhao L, Song Y., Free PMC Article | 12/21/2019 |
| study revealed that miR-219a-5p function as tumour suppressor regulates osteosarcoma cell invasiveness by repressing EYA2 expression. | miR-219a-5p represses migration and invasion of osteosarcoma cells via targeting EYA2.
Zhu X, Chen L, Lin J. | 06/22/2019 |
| our data indicate that Eya2 may serve as a potential oncoprotein in human astrocytoma. Eya2 regulates astrocytoma cell proliferation and invasion, possibly through the regulation of ERK signaling. | Eya2 overexpression promotes the invasion of human astrocytoma through the regulation of ERK/MMP9 signaling.
Wen Z, Liang C, Pan Q, Wang Y., Free PMC Article | 06/2/2018 |
| EYA2 knockdown led to decreased metastatic spread of breast cancer cells to the lung and greatly attenuated the ability of EGFR to regulate the epithelial-to-mesenchymal transition markers. | The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.
Liang Y, Xu X, Wang T, Li Y, You W, Fu J, Liu Y, Jin S, Ji Q, Zhao W, Song Q, Li L, Hong T, Huang J, Lyu Z, Ye Q., Free PMC Article | 05/19/2018 |
| High EYA2 expression is associated with acute myeloid leukemia. | Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.
Ono R, Masuya M, Ishii S, Katayama N, Nosaka T., Free PMC Article | 09/16/2017 |
| EYA2 functions as a stimulant in lung adenocarcinoma pathogenesis. | Aberrant hypomethylation and overexpression of the eyes absent homologue 2 suppresses tumor cell growth of human lung adenocarcinoma cells.
Gao T, Zheng S, Li Q, Ran P, Sun L, Yuan Y, Xiao C. | 04/29/2017 |
| results demonstrate that overexpression of miR-30a in lung adenocarcinoma A549 cells can inhibit cell migration and invasion, which is partially attributed to the decrease of EYA2 expression | Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2.
Yuan Y, Zheng S, Li Q, Xiang X, Gao T, Ran P, Sun L, Huang Q, Xie F, Du J, Xiao C., Free PMC Article | 12/17/2016 |
| SIX1 and EYA are often co-overexpressed in tumors, and the SIX1-EYA2 interaction has been shown to be critical for metastasis in a breast cancer model. | The SIX1-EYA transcriptional complex as a therapeutic target in cancer.
Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL., Free PMC Article | 09/5/2015 |
| Decreased expression of EYA2 is associated with pancreatic adenocarcinomas. | Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth.
Vincent A, Hong SM, Hu C, Omura N, Young A, Kim H, Yu J, Knight S, Ayars M, Griffith M, Van Seuningen I, Maitra A, Goggins M., Free PMC Article | 02/21/2015 |
| This interaction suggests that CDK6 regulates EYA2 activity, a mechanism that could be important in development and in cancer. | CDK6 binds and promotes the degradation of the EYA2 protein.
Kohrt D, Crary J, Zimmer M, Patrick AN, Ford HL, Hinds PW, Grossel MJ., Free PMC Article | 09/6/2014 |
| MIR30A represses Eya2 expression by binding to the 3'-untranslated region of Eya2.The MIR30A/EYA2 axis regulates breast cancer cell proliferation and migration. | miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2.
Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J, Cheng L, Fan Z, Yuan B, Tian P, Zheng X, Yu C, Ye Q, Lv Z. | 06/7/2014 |
| Functional roles of candidate genes EYA2 (20q13) and hsa-miR-375 (2q35) were studied by siRNA-mediated knock-down and overexpression, respectively, in hrHPV-containing cell lines. | Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis.
Bierkens M, Krijgsman O, Wilting SM, Bosch L, Jaspers A, Meijer GA, Meijer CJ, Snijders PJ, Ylstra B, Steenbergen RD. | 07/27/2013 |
| Given that SIX1 and EYA are overexpressed in many tumor types, our data indicate that targeting the SIX1-EYA complex may be a potent approach to inhibit tumor progression in multiple cancer types | Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome.
Patrick AN, Cabrera JH, Smith AL, Chen XS, Ford HL, Zhao R., Free PMC Article | 06/15/2013 |
| Studies indicate that the RNA and protein levels of Eya2 is upregulated in ovarian cancer. | Human HAD phosphatases: structure, mechanism, and roles in health and disease.
Seifried A, Schultz J, Gohla A. | 04/13/2013 |
| Data implicate Eya2 as a necessary co-factor for many of the metastasis promoting functions of Six1. | Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.
Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL., Free PMC Article | 03/31/2012 |
| Expression of EYA2 in lung adenocarcinoma is augmented. | [Expression of EYA2 in non-small cell lang cancer].
Guo JT, Ding LH, Liang CY, Zhou NK, Ye QN. | 10/23/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium., Free PMC Article | 09/15/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| Based on observation that the dachshund-binding site is located between the catalytic core & Sine Oculis binding sites within ED-Eya2, we propose that catalytic activity can be translated to SO binding through DAC, which acts as a transcriptional switch. | Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor.
Jung SK, Jeong DG, Chung SJ, Kim JH, Park BC, Tonks NK, Ryu SE, Kim SJ., Free PMC Article | 03/1/2010 |